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We aimed to evaluate the diagnostic and prognostic value of measuring survivin levels, which is
an inhibitor of apoptosis in pleural effusions. Methods: Group I, malignant (MPE) (n Z 51);
Group II, tuberculosis (TPE) (n Z 18); Group III transudative (TE) (n Z 9) effusions were
enrolled prospectively. We used ELISA to analyze 78 effusions. The value for the differential
diagnosis and the correlation between survivin and survival in MPE were analyzed. Results: Sur-
vivin level was 41.75  76.20 in MPE, 15.83  10.92 in TPE and 8.33  8.67 in TE. When the
patients divided two groups as malignant and non-malignant pleural effusion (non-MPE), survi-
vin level was significantly higher in MPE (41.75  76.20) than in non-MPE (13.332.05)
(p Z 0.012). The cutoff value for survivin levels detected by ROC curve analysis was 7.5 pg/
ml, with sensitivity and specificity values of 72%, 44%, respectively. Survivin had no discrimina-
tive power in differentiating exudative effusions of MPE from TPE (p Z 0.405). There was no
correlation between survivin level and age, sex, location, fluid pH, glucose, protein, albumine
and ADA level while there was significant moderate correlation with fluid LDH (r Z 0.49;
p < 0.001). Survivin levels can distinguish patients who had poor prognosis (median survival
75 days, n Z 24) and those who had good prognosis (median survival 219 days, n Z 27,
p Z 0.03) in MPE.
In conclusion, survivin expression levels detected with ELISA had no discriminative power in
differentiating exudative effusions included MPE and TPE. Elevated survivin levels are associ-
ated with poor survival in MPE. Our results suggest that survivin may be a potential prognostic
marker in MPE.
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diagnosed according to criteria cited below which wasMalignant pleural effusion (MPE) is a common and impor-
tant cause of cancer-related mortality and morbidity. 1,2
Prompt diagnosis using minimally invasive test is impor-
tant because the median survival after diagnosis is only 4e9
months. The sensitivity of cytologic examination of pleural
effusion is variable with limited sensitivity and not pre-
dictive of prognosis.3,4 Consequently, many patients need
to undergo invasive diagnostic tests such as thoracoscopic
pleural biopsy. Besides, none of the prognostic marker has
been validated until now for MPE.
Survivin is an inhibitor of apoptosis that may be a novel
diagnostic and prognostic marker of cancer. It is selectively
upregulated in many human tumors, where its over-
expression correlates with poor outcome.5e9 Tissue
expression of survivin has a critical role for diagnosis,
prognosis and the prediction of response to therapy.5,7,8
But, there are limited data on the expression and prog-
nostic role of survivin in malignant pleural effusion.10e13 So,
its value in the analysis of biological fluids such as pleural
effusion is not known.
We aimed to determine the discriminative power of
survivin in proven cases of MPE and non-MPEs diagnosed by
conventional cytopathologic and histopathologic methods,
and testing the prognostic value of survivin levels in MPE.Materials and methods
Subjects
Between October 2009 and July 2010, a total of 78 patients
[51 with malignant, 18 with tuberculosis and 9 with
congestive heart failure (CHF)] with pleural effusion
admitted to our clinic were included in the study. All pa-
tients consecutively diagnosed with MPE, tuberculousTable 1 Distribution of patients according to primary etiology.
N (%) Surv
Malignant pleural effusion 51 (65) 41.7
Primary lung carcinoma 24 5
Adeno 22
Squamous 1
Small cell carcinoma 1
Metastatic other than lung 14 2
Breast 6
Pancreas 2
Colon 1
Gastrointestinal system 1
Prostate 1
Adenoid cystic carcinoma 1
Cervix 1
Unknown primary 1
Mesothelioma 8 1
Lymphoma 5 8
Tuberculosis (TPE) 18 (23) 15.8
Congestive Heart Failure (CHF) 9 (12) 8.3
a No statistically significant difference was found between the tumpleurisy (TPE) and CHF were included. All patients were
considered as a reasonable standard for diagnosis. Distri-
bution of patients according to the primary etiology has
been shown in Table 1.
Medical history was taken from all patients included in
the study. Physical examination was made, and poster-
oanterior chest X-ray ordered. Thoracentesis was carried
out in all patients. Total protein, albumin, LDH, glucose and
pH were measured in the pleural fluid and blood sample,
and ADA levels also were studied in pleural fluid. In addi-
tion, fluid cell formula and acid-fast bacilli were analyzed
in effusions in the microbiology laboratory.
The diagnosis of TPE was done according to the following
criteria; (1) Pathological demonstration of a necrotizing
granulomatous inflammation in the pleural tissue sample
taken with closed biopsy or Video Assisted Thoracoscopic
Surgery (VATS) (17 patients); or (2) microbiologic isolation
of Mycobacterium tuberculosis in the pleural fluid (2 pa-
tients); plus exclusion of other possible diagnosis by clinical
and radiological examination.
The diagnosis of MPE was done according to the
following criteria; malignant cells in the cytology of the
pleural fluid (27 patients) and/or on histopathologic ex-
amination of the pleural tissue obtained by VATS (6 pa-
tients) or pleural blind biopsy (18 patients).
The diagnosis of CHF is based on medical history, phys-
ical examination and detection of cardiomegaly in chest X-
ray. Left ventricular systolic dysfunction on echocardiog-
raphy and response to diuretic therapy was also used in the
confirmation of the diagnosis.
Methods
Study has been approved by the ethical committee and
informed consents were obtained from all participants.
From each patient 5 ml aliquots of pleural fluid wereivin levels (pg/ml) Survival, median  SE (95% CI)
5  76.20
2  95a 75  4 (67e82)
5  20 45  67 (0e177)
8  22 181  29 (122e239)
6  124 215  119 (0e449)
3  10.92
3  8.67
or groups according to survivin level (p Z 0.22).
Table 2 Demographical features of patients.
(MPE) (n Z 51) (TPE) (n Z 18) CHF (n Z 9) p
Age (mean) 60.20  13.91 34.22  14.39 75.22  8.25 0.000**
Age (min-max) 20e80 18e63 59e85
Sex (F/M) 22/29 7/11 1/8 0.135
Smoking (p/y) 30 (73.5%) 8 (44.4%) 5 (55.6%) 0.945
Alcohol 5 (9.4%) 2 (11.1%) 0 0.383
Asbest expose 19 (35.8%) 0 0 0.000**
ECOG
1 15
2 19
3 13
4 4
One-way ANOVA, c2 test, p < 0.05 is significant **.
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4000 rpm for 10 min at 4 C, supernatants were dispensed
into 2 ml Eppendorf tubes and were refrigerated at 20 C.
For the survivin measurement, samples were transported to
the Istanbul University Cerrahpas‚a Faculty of Medicine,
Department of Microbiology on ice where they were kept at
80 C until to work-up.
In this study, Human Total Survivin Enzyme Immuno-
metric Assay Kit (TiterZyme EIA, Assay Design, Inc., Ann
Arbor, MI, USA; Catalog # 900-111) was used. According the
package insert of the kit the dynamic range of the assay
was between 31.25 and 1000 pg/ml and the lower limit of
the detection was 3.6 pg/ml. All pleural effusion samples
and regents were kept on bench until they reached to the
room temperature. All the processes were carried out at
room temperature according to instructions of the
manufacturer.
Statistical analysis
Patient demographics and disease characteristics were
summarized using descriptive statistics. Sensitivity, speci-
ficity, positive predictive value, and negative predictive
value were calculated. All continuous data were expressed
as mean and standard deviation, and categorical variables
as frequency and percentage. Statistical mean difference
between the groups was analyzed with Student t-test and in
case of more than two groups with one-way ANOVA test. In
case of a significant difference with one-way ANOVA test,
Tukey HSD was used for post-hoc analysis to define the
groups from which the difference arose. Chi-square test
was used in categorical variables. The groups were properly
combined, and the analysis was repeated if expected fre-
quency was less then 5 in one of the cells. For 2  2 con-
tingency tables Yates correction was done and Fisher’s
exact test was used if expected frequency was less then 5 in
one of the cells. In bivariate correlations studied with
survivin, Spearmen’s correlation test was used as the dis-
tribution of survivin was not normal. KaplaneMeier was
used in survival analysis and survival difference between
groups was studied with the log-rank test. To analyze fac-
tors that effected survival, Cox regression test was used in
which survivin level, fluid LDH level and tumor types wereincluded as independent variables. In the first model all
independent variables were included and in the second
model backward elimination with likelihood ratio was used
to construct the model. Statistical significance was set at
p < 0.05. SPSS for Windows, version 16 package program
has been used for statistical analysis.Results
Our study was carried out with 78 patients [M/F: 48 (61%)/
30 (39%), age (18e80 years)], referred to Yedikule Chest
Disease and Thoracic Surgery Training and Research Hos-
pital, and diagnosed with MPE, TPE and CHF between
October 2009 and July 2010. Of the MPE cases, 27 (53%)
were diagnosed with fluid cytology, 18 (34%) with blind
pleural biopsy and 6 (13%) with VATS. Acid-fast bacillus was
found in fluid smear and Mycobacterium tuberculosis iso-
lated in culture of two patients, chronic granulomatous
inflammation in pleural biopsy of 17 patients with TPE, and
beside that definitive diagnosis was made ruling out the
other possibilities. Distribution of the patients according to
the diagnoses is shown in Table 1 and demographic char-
acteristics in Table 2.
Survivin levels in study populations
Mean value of survivin in MPE, TPE and CHF were
41.75  76.20 pg/ml, 15.83  10.92 pg/ml, and
8.33  8.67 pg/ml respectively. Mean value of survivin
tended to be higher in MPE, but no statistically significant
difference was found between the three
groups (p Z 0.182). When the patients were divided into
two groups as malignant and non-malignant pleural effu-
sion, mean level of survivin was found to be significantly
higher in malignant effusions compared to non-malignant
group (41.75  76.20 versus 13.3310.69, p Z 0.012)
(Fig. 1).
In the group of MPE, mean levels of survivin according to
tumor origins are reported on Table 1. No statistically sig-
nificant difference was found between the groups accord-
ing to survivin level (p Z 0.22). Patients histologically
diagnosed with an adenocarcinoma were divided into two
Figure 1 Comparisons of survivin levels between malignant
and non-malignant effusions (41.75  76.20 versus
13.33  10.69).
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lung cancer. Mean levels of survivin were found as
54.9  98.9 in primary lung adenocarcinoma (n Z 21) and
31.44  21.76 in extrapulmonary metastatic adenocarci-
noma (n Z 9). No statistically significant difference was
found between the groups according to survivin level
(p Z 0.31).Figure 2 ROC analysis for survivin expression in pleural
effusion. The plot was constructed by computing the sensitivity
vs. (1  specificity) for the different possible cutoff points of
the survivin ELISA assay.When all patients were evaluated, a significant moder-
ate correlation was found between survivin level and fluid
LDH (r Z 0.49; p < 0.001) levels. In the MPE group, mod-
erate correlation was found between survivin level and
fluid LDH (r Z 0.47; p Z 0.001) levels. No significant cor-
relation was found in terms of age, gender, side of fluid,
amount, appearance, pH, glucose, protein, albumin and
ADA of fluid.
Discriminative power of survivin in MPE
ROC curve was created to find sensitivity and specificity of
survivin level in MPE vs non-MPE group. Area under the ROC
curve was 0.63  0.06 (SE) (p Z 0.066) (%95 CI
0.505e0.747). Considering cutoff value as 7.5 pg/ml,
sensitivity was found as 72% and specificity as 44%. ROC
curve is shown in Fig. 2. The ROC curve has also been drawn
for MPE and TPE which were two significant etiological
reason for exudative effusions. Area under the ROC curve
was 0.566  0.067 (p Z 0.405) (%95 CI 0.434e0.698). Ac-
cording to our results, survivin had no discriminative power
in differentiating exudative effusions of MPE and TPE.
When the ROC curve was drawn with MPE and CHF area
under the ROC curve was 0.75  0.08(SE) (p Z 0.019) (%95
CI 0.596e0.897). Considering cutoff value as 7.5 pg/ml,
sensitivity was found as 72% and specificity as 78%.
Prognostic value of survivin among MPE patients
KaplaneMeier survival analysis was performed in the MPE
group. Survival was better in combined lymphoma and
mesothelioma groups compared to malignant fluids due to
combined primary lung cancer and metastatic lung cancer
groups (p Z 0.015, Log-rank (ManteleCox)). The worst
median survival was found in malignant fluids related with
extrapulmonary primary tumors. Considering the patients
diagnosed with an adenocarcinoma subtype in MPE group,
no statistically significant difference was found between
primary lung and other than lung groups in survival analysis.
Survivin levels (cutoff determined by the median value of
survivin ie >20 pg/ml vs <20 pg/ml) can distinguish pa-
tients who had poor prognosis (median survival 75 days,
nZ 24) and those who had good prognosis (median survival
219 days, n Z 27, p Z 0.03). Elevated levels of survivin
were related to reduced overall survival in KaplaneMeier
analysis (Fig. 3).
Cox regression analysis was carried out for significant
factors influencing survival. Survivin level, fluid LDH level
and tumor type were included as independent factors. Only
survivin level was retained as significant in backward
elimination likelihood ratio test. (Table 3)
Discussion
Survivin is a 16.5 kDa protein that inhibits apoptosis, pro-
mote proliferation, and has a crucial role in the develop-
ment of cancer. Survivin is selectively upregulated in many
human tumors, where its overexpression correlates with
poor outcome6e9 and chemotherapy/radiotherapy resis-
tance.7,8 In a recent meta-analyses, it was suggested that
the survivin 31G>C promoter polymorphism might be
Figure 3 KaplaneMeier survival curve showing the association between survivin expression and overall survival (p Z 0.03).
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Asian populations.14 Conflicting results have been published
in the association between survivin levels in serum and the
risk/prognosis of cancer.15,16 However, survivin detection in
urine appears to be a highly predictive molecular marker of
bladder cancer.17
Only a few studies have been conducted in pleural
effusion for evaluating a diagnostic and prognostic role of
survivin.10,11 Dong et al.11 showed that the sensitivity of the
diagnosis for lung cancer and negative predicted value
increased when cytological examination of pleural effusion
and detection of survivin mRNA in pleural effusion was
combined. Lan et al.12 have reported that survivin mRNA
levels were significantly higher in MPEs. Overexpression of
survivin mRNA correlated with poor prognosis in cancer
patients.12
Wu et al.18 had been the first authors to have analyzed
pleural effusion specimens for survivin expression using
ELISA. They reported remarkable sensitivity and specificity
with a cutoff value of 0.0062 ng/ml. The limitation of their
study was that non-malignant group has limited number of
TPE patients (n Z 9). Interestingly, more than half of the
TPE patients (5/9) expressed survivin in the same study.
Specificity can reach 100% when TPE patients were
excluded from study. It is known that TPE is frequently
diagnosed as the cause of exudative pleural effusion in Asia
and in our country. Our study included 18 TPE diagnosed by
biopsy or culturing of the mycobacterium. Survivin levelsTable 3 Cox regression analysis of survival data.
Model c2: 5.30 (p Z 0.02)
b SE p Value eb
Survivin 0.005 0.002 0.027 1.005were higher in MPE group (41.75 pg/ml) when compared
with TPE (15.83 pg/ml). However, according to our results,
survivin had no discriminative power in differentiating
exudative effusions of MPE from TPE (p Z 0.405) (%95 CI
0.434e0.698).
ROC curves for MPE versus non-MPE were analyzed and
for the cutoff value of 7.5 pg/ml sensitivity was 72% and
specificity 44%. When TPE cases were excluded, for the
same cutoff value of 7.5 pg/ml sensitivity was 72% and
specificity was improved to 78% and was statistically sig-
nificant. Our results showed increased specificity when TPE
patients were excluded, although our group included
limited number of CHF transudative effusions. Since this
study was made in a country where tuberculosis is endemic,
discrimination between exudative effusions of MPE and TPE
was very important and survivin had no discriminative
power in such cases.
No association has been detected between survivin
levels of pleural effusion and age, sex, performance status,
stage of tumor and subgroup of disease similar to our
findings.18 The correlation between survivin levels in pleura
and fluid LDH was moderate in our study (r Z 0.49;
p < 0.001). There are studies that report the prognostic
importance of LDH levels. 19 However in our study, Cox
regression analysis did not retain LDH levels as a significant
factor in survival and only survivin was found significant. It
may be that survivin may overshadow the prognostic effect
of LDH because of their correlation.
Mesothelioma and lymphoma have better long-term
survival compared with metastatic effusion related with
lung and other solid tumors (p Z 0.015). In addition pa-
tients with mesothelioma had lower levels of survivin
though comparison between tumor types did not reach
statistical significance. No statistically significant differ-
ence of survivin was found between adenocarcinoma pa-
tients according to primary site in lung or others (pZ 0.31).
Prognostic significance of survivin in malignant pleural effusion 1265However in Cox regression analysis, tumor type was not
retained as significant factor in survival. According to pre-
vious studies increased survivin levels or mRNA expression
in pleural effusion were associated with poor sur-
vival.12,13,18 In our study, elevated levels of survivin was
correlated with a reduced overall survival. Survivin levels
can clearly distinguish patients as a poor and good prog-
nostic group.
In our study, survivin level was analyzed with ELISA
technique. In studies of a limited number in the literature,
survivin levels were studied with various methods such as
mRNA with PCR, IHC, immunoblotting and ELISA. Analysis
using various methods limits the studies and makes it
difficult to compare results.
In conclusion, survivin levels can be elevated both in
inflammation and malignancies.20 It can be suggested that
positive values of survivin might be misleading in the re-
gions with a high prevalence of TPE like our country and
cannot be used as a safe diagnostic tool in differentiation
between TPE and MPE. Therefore, TPE group limits the use
of survivin in differential diagnosis of MPE can lead to false-
positive results. However, its questionable diagnostic role
aside survivin has a potential role as a remarkable prog-
nostic marker for MPE.
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